Gene Editing May Help Treat Dangerously High Cholesterol with Just One Infusion
A new gene-editing therapy, VERVE-102, shows promise in treating familial hypercholesterolaemia with just one infusion. Early clinical trial results indicate that this treatment can significantly lower harmful cholesterol levels for at least a year. Experts believe this approach could revolutionize cholesterol management and reduce reliance on daily medications.
- ▪VERVE-102 is a gene-editing therapy developed by Verve Therapeutics, a subsidiary of Eli Lilly.
- ▪The therapy targets the PCSK9 gene in the liver, which regulates harmful cholesterol levels in the bloodstream.
- ▪In a trial of 35 patients, cholesterol levels dropped significantly, with some maintaining lower levels for over a year.
Discover Magazine files mainly under science. We currently carry 86 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Discover Magazine |
| Canonical URL | https://www.discovermagazine.com/gene-editing-may-help-treat-dangerously-high-cholesterol-with-just-one-infusion-49177 |
| Publication time | Fri, 29 May 2026 21:30:00 GMT |
| Retrieval time | 2026-05-29T21:40:35.524Z |
| Last seen | 2026-05-29T21:40:35.524Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | MaVhqpqjvjaF |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
For people born with familial hypercholesterolaemia, an inherited condition that causes dangerously high cholesterol from birth, managing it isn't a lifestyle choice. It's a daily obligation: pills every morning, injections every few weeks, a regimen that begins young and, for most, never ends. A new experimental therapy aims to change that with one infusion.Results from an early clinical trial, published in the New England Journal of Medicine, show that one dose of VERVE-102, a gene-editing therapy developed by Verve Therapeutics, a subsidiary of Eli Lilly, can lower harmful cholesterol in patients with the inherited condition or early-onset heart disease.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Discover Magazine.
Discussion
0 commentsMore from Discover Magazine
